View Older Stories View More Recent Stories

Mar 19, 2024 08:16AM Seelos Therapeutics (SEEL) Provides Update on Top-Line Results from its ALS Study
Mar 19, 2024 08:15AM Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
Jan 22, 2024 08:01AM Seelos Therapeutics (SEEL) Receives Minutes from its End of Phase II Meeting with the FDA
Jan 22, 2024 08:00AM Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endp
Jan 2, 2024 08:00AM Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
Dec 22, 2023 08:02AM Seelos Therapeutics (SEEL) Issues Letter to its Stockholders
Dec 22, 2023 08:00AM Seelos Therapeutics, Inc. Releases Letter to its Stockholders
Nov 27, 2023 08:04AM Seelos Therapeutics (SEEL) Announces Selection of SLS-002 for Inclusion in U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for PTSD
Nov 27, 2023 08:00AM Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post
Oct 27, 2023 08:11AM Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
Oct 17, 2023 08:02AM Seelos Therapeutics (SEEL) Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
Oct 17, 2023 08:00AM Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
Sep 27, 2023 08:01AM Seelos Therapeutics (SEEL) Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
Sep 27, 2023 08:00AM Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
Sep 20, 2023 07:01AM Seelos Therapeutics (SEEL) Reports Top Line Results from SLS-002 Phase II Study in Adults
Sep 20, 2023 07:00AM Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
Aug 14, 2023 08:00AM Seelos Therapeutics Provides Second Quarter 2023 Clinical Update
Jun 22, 2023 08:00AM Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major D
May 22, 2023 08:00AM Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
May 15, 2023 08:00AM Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
May 5, 2023 08:00AM Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
Apr 4, 2023 08:00AM Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program
Mar 29, 2023 04:05PM Seelos Therapeutics Announces Business Update on its Key Programs
Feb 15, 2023 09:21AM Seelos Therapeutics to Participate in 43rd Annual Cowen Health Care Conference
Feb 13, 2023 08:00AM Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
Feb 10, 2023 08:00AM Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
Feb 6, 2023 08:00AM Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
Dec 22, 2022 08:00AM Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event
Dec 15, 2022 08:02AM Seelos Therapeutics (SEEL) Reports Strong SLS-004 Data
Dec 15, 2022 08:00AM Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease
Dec 8, 2022 08:00AM Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022
Nov 23, 2022 08:00AM Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022
Nov 7, 2022 12:56PM Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day
Oct 27, 2022 08:00AM Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event
Oct 25, 2022 08:00AM Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia
Sep 30, 2022 10:01AM Seelos Therapeutics (SEEL) to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program
Sep 30, 2022 10:00AM Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the A
Sep 13, 2022 08:00AM Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients wi
Sep 9, 2022 09:00AM Seelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference
Aug 30, 2022 08:00AM Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences
Aug 24, 2022 08:00AM Seelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004
Jul 18, 2022 08:00AM Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform
Jun 9, 2022 08:02AM Seelos Therapeutics (SEEL) Reports Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004
Jun 9, 2022 08:00AM Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 i
May 18, 2022 08:05AM Seelos Therapeutics (SEEL) Receives Notice of Allowance in the U.S. for an Additional Patent for SLS-007
May 18, 2022 08:00AM Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
May 12, 2022 08:00AM Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
Apr 22, 2022 11:00AM Seelos Therapeutics to Participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference
Apr 11, 2022 08:06AM Seelos Therapeutics (SEEL) Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002
Apr 11, 2022 08:00AM Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Com
View More Recent Stories View Older Stories